Karen Knudsen: Clinical trials driving cancer care breakthroughs
Karen Knudsen, Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS), posted the following on LinkedIn:
“The data are clear—cancer research saves lives, and nowhere is this more apparent than in the form of clinical trials. Clinical trials represent the most advanced form of cancer care… vital for patients with advanced cancers who have exhausted other options and equally critical for developing new strategies for early detection and cures. These trials have played a pivotal role in the 34% reduction in cancer mortality since 1991, a remarkable achievement that reflects decades of innovation and dedication in oncology research.
Much of this progress comes via the National Cancer Institute (NCI), which is too often an unsung hero in the story about cancer cures. As reported, NCI allocated $857.6M (or ~12.5% of its $6.833B budget) to cancer clinical trials. This funding underpins breakthroughs in cancer care that save lives, offering hope to millions.
In short, this is a reminder that real lives are on the line. For patients, for families, and for the future of cancer care, it’s critical to ensure uninterrupted support for NCI research and clinical trials.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023